Jaydutt Bhalshankar YOU? Author Swipe

Last 10y

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Angela Bellini, Chiara Gorrini, Elizabeth Calton , et al. · 2025

PDX data and clinical data

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Elizabeth Calton , et al. · 2025

GEMM ALK inhibitor data

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Chiara Gorrini, Elizabeth Calton , et al. · 2025

Cell line and PDX genetics

Supplementary Table 2 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table 2

Supplementary Table 1 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table 1

Supplementary Table Legend 1 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table Legend

Supplementary Table 1 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table 1

Supplementary Table 3 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table 3

Supplementary Table Legend 1 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table Legend

Supplementary Table 4 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table 4

Supplementary Table 3 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table 3

Supplementary Table 2 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table 2

SupplemetaryFigure1-5 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

SupplemetaryFigure12345

SupplemetaryFigure1-5 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

SupplemetaryFigure12345

Data from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Purpose:The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma.Experimental Design:Eighteen patients with relapsing neuroblastoma having received lorlatinib,…

Supplementary Table 4 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Supplementary Table 4

Data from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i>-Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Purpose:The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma.Experimental Design:Eighteen patients with relapsing neuroblastoma having received lorlatinib,…

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving <i>ALK</i> -Targeted Therapy Open

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon, Alexandra Saint‐Charles , et al. · 2024

Purpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatin…

Analyse bioinformatique intégrative de l'hétérogénéité intra-tumorale dans le neuroblastome au niveau de la cellule unique Open

Jaydutt Bhalshankar · 2024

In this comprehensive study, we delve into the genetic heterogeneity of neuroblastoma (NB), a challenging pediatric solid tumor, by leveraging the power of single-cell and bulk sequencing technologies.Our investigation is two-fold: firstly…

Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma Open

Cécile Thirant, Agathe Peltier, Simon Durand, Amira Kramdi, Caroline Louis‐Brennetot , et al. · 2023

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

Cell line and PDX genetics

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

GEMM ALK inhibitor data

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

Cell line growth curves and PDX data for idasanutlin combination

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

GEMM ALK inhibitor data

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

Cell line and PDX genetics

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

PDTC experimental data

Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

Supplementary methods, supplementary tables, supplementary figure legends

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

PDX data and clinical data

Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

Supplementary methods, supplementary tables, supplementary figure legends

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Open

Elizabeth R. Tucker, Irène Jiménez, Lindi Chen, Angela Bellini, Chiara Gorrini , et al. · 2023

Cell line growth curves and PDX data for idasanutlin combination

Fetching topic information...